Jefferies Financial Group Initiates Coverage on Immunocore (NASDAQ:IMCR)

Equities research analysts at Jefferies Financial Group assumed coverage on shares of Immunocore (NASDAQ:IMCR) in a report released on Monday. The brokerage set a “buy” rating and a $48.00 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 44.97% from the stock’s current price.

Several other research firms also recently commented on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Monday, June 2nd. Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a “buy” rating and a $65.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.89.

Immunocore Trading Up 0.5%

Shares of IMCR stock traded up $0.18 on Monday, reaching $33.11. 4,007 shares of the company’s stock were exchanged, compared to its average volume of 335,802. The stock has a market capitalization of $1.67 billion, a PE ratio of -82.78 and a beta of 0.77. Immunocore has a 52 week low of $23.15 and a 52 week high of $39.33. The company’s fifty day simple moving average is $33.30 and its 200 day simple moving average is $31.29. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.01. The company had revenue of $130.65 million for the quarter, compared to the consensus estimate of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm’s revenue was up 30.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.23) EPS. As a group, analysts forecast that Immunocore will post -0.94 EPS for the current year.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its holdings in Immunocore by 5.2% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company’s stock worth $209,228,000 after acquiring an additional 351,610 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunocore by 40.8% during the second quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company’s stock worth $118,349,000 after buying an additional 1,092,824 shares in the last quarter. Bellevue Group AG grew its holdings in shares of Immunocore by 99.9% during the second quarter. Bellevue Group AG now owns 2,441,830 shares of the company’s stock worth $76,625,000 after buying an additional 1,220,036 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Immunocore by 53.3% during the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company’s stock worth $68,913,000 after buying an additional 807,338 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company’s stock worth $64,533,000 after buying an additional 29,832 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.